Calls Now Open

2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs

You've just added:

Home / News

News + Media

October 18, 2021

Researchers Awarded $12 Million to Pursue Personalized Therapies for Severe Asthma

INDIANAPOLIS— A group of researchers led by Indiana University School of Medicine’s , has been awarded a research program project grant (P01) from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalized therapeutic... Continue Reading

October 11, 2021

Tackling Dystonia with an Approved Drug

Dystonias are a group of chronic movement–disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The availability of an oral drug with disease-modifying potential would transform the current treatment landscape. 2015 Harrington Scholar-Innovator Nicole Calakos, MD, PhD... Continue Reading

October 11, 2021

Small-Molecule Suppression of Calpastatin Degradation Reduces Neuropathology in Models of Huntington’s Disease

Huntington’s Disease (HD) is a fatal neurological disorder caused by a trinucleotide CAG repeat expansion in the N-terminal exon 1 of the huntingtin (Htt) gene. HD manifests as uncontrolled involuntary movements accompanied by progressive motor and cognitive deficits, psychiatric disturbance, and dementia. There is no therapy... Continue Reading

August 19, 2021

Oxford-Harrington Partnership Targets FA as First Priority

Scientists on either side of the Atlantic have teamed up, through the new (OHC), to address unmet needs in rare disease research and deliver “major clinical impact” to patients.And now, the international collaboration between the University of Oxford, in England, and the Harrington Discovery Institute, in Cleveland, Ohio... Continue Reading

August 18, 2021

New Study Finds Therapeutic Treatment Option for Metabolic Syndrome, Obesity

CLEVELAND—Metabolic syndrome is a cluster of conditions and includes obesity, and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. In a recent study, published in , researchers at Harrington Discovery Institute at University Hospitals (UH) have discovered a therapeutic option... Continue Reading

August 02, 2021

Nominations Open for 9th Annual Harrington Prize for Innovation in Medicine

CLEVELAND, Ohio – National and international nominations are being sought for the 2022 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.The Harrington Prize, which... Continue Reading

July 13, 2021

Harrington Discovery Institute Announces 2021 Scholar-Innovator Award Recipients

CLEVELAND, Ohio – The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2021 class of Harrington Scholar-Innovators. The scholar awards will support a diverse set of drug discovery projects including new treatments for multiple cancers, cardiovascular disease, Graft vs. Host... Continue Reading

July 01, 2021

The Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute to Support Promising Research to Restore Brain Function in People with Alzheimer’s Disease

NEW YORK, NY – The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted to two Principal Investigators, Paul Fish, Ph.D., of University College London’s Drug Discovery Institute and Paul Worley, M.D., of Johns Hopkins University.Dr. Fish and Dr.... Continue Reading

May 30, 2021

Amgen to Acquire Rodeo Therapeutics Corporation

Preclinical program targeting 15-PGDH has potential use in a broad range of therapeutic applications including inflammatory disease indications Continue Reading

March 29, 2021

The Harrington Discovery Institute Supports COVID-19 Antibody Therapy Development at the Rockefeller University

NEW YORK, NY, March 29, 2021—The Rockefeller University has received supplemental grant support from the Harrington Discovery Institute to help fund the testing of a monoclonal antibody drug for the prevention and early treatment of COVID-19. The drug is the result of a collaborative research effort launched in the first... Continue Reading

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.